Cargando...
Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment
Repurposing of approved antiviral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising strategy to treat Coronavirus disease 2019 (COVID-19) patients. Previously we reported our hypothesis that the antiviral drugs with high lung distributions might benefit COVID-...
Gardado en:
| Publicado en: | Eur J Pharmacol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Elsevier B.V.
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7536545/ https://ncbi.nlm.nih.gov/pubmed/33031797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejphar.2020.173634 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|